These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11337297)

  • 1. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study.
    Mohr BA; Feldman HA; Kalish LA; Longcope C; McKinlay JB
    Urology; 2001 May; 57(5):930-5. PubMed ID: 11337297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of sex hormone levels and risk of prostate cancer.
    Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ
    J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway.
    Vatten LJ; Ursin G; Ross RK; Stanczyk FZ; Lobo RA; Harvei S; Jellum E
    Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):967-9. PubMed ID: 9367072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland.
    Dorgan JF; Albanes D; Virtamo J; Heinonen OP; Chandler DW; Galmarini M; McShane LM; Barrett MJ; Tangrea J; Taylor PR
    Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1069-74. PubMed ID: 9865423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgens and prostate cancer risk: a prospective study.
    Wirén S; Stocks T; Rinaldi S; Hallmans G; Bergh A; Stenman UH; Kaaks R; Stattin P
    Prostate; 2007 Aug; 67(11):1230-7. PubMed ID: 17562541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.
    Schenk JM; Till C; Hsing AW; Stanczyk FZ; Gong Z; Neuhouser ML; Reichardt JK; Hoque AM; Figg WD; Goodman PJ; Tangen CM; Thompson IM
    Cancer Causes Control; 2016 Feb; 27(2):175-82. PubMed ID: 26589415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ; Azen CG; Pike MC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study.
    Gray A; Feldman HA; McKinlay JB; Longcope C
    J Clin Endocrinol Metab; 1991 Nov; 73(5):1016-25. PubMed ID: 1719016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous sex hormones and the risk of prostate cancer: a prospective study.
    Weiss JM; Huang WY; Rinaldi S; Fears TR; Chatterjee N; Hsing AW; Crawford ED; Andriole GL; Kaaks R; Hayes RB
    Int J Cancer; 2008 May; 122(10):2345-50. PubMed ID: 18172860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.
    Chen C; Weiss NS; Stanczyk FZ; Lewis SK; DiTommaso D; Etzioni R; Barnett MJ; Goodman GE
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1410-6. PubMed ID: 14693730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III).
    Rohrmann S; Nelson WG; Rifai N; Kanarek N; Basaria S; Tsilidis KK; Smit E; Giovannucci E; Platz EA
    Urology; 2007 Apr; 69(4):708-13. PubMed ID: 17445656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of serum androgens and pituitary hormone levels with serum PSA less than 2.5 ng/ml.
    Sofikerim M; Oruç O; Eskicorapci S; Guliyev F; Ozen H
    ScientificWorldJournal; 2007 Jul; 7():1128-33. PubMed ID: 17660883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum androgens and prostate cancer.
    Nomura AM; Stemmermann GN; Chyou PH; Henderson BE; Stanczyk FZ
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):621-5. PubMed ID: 8824364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating steroid hormones and the risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley W; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):86-91. PubMed ID: 16434592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen in female serum, a potential new marker of androgen excess.
    Melegos DN; Yu H; Ashok M; Wang C; Stanczyk F; Diamandis EP
    J Clin Endocrinol Metab; 1997 Mar; 82(3):777-80. PubMed ID: 9062481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
    Cochran RC; Ewing LL; Niswender GD
    Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer.
    Peskoe SB; Joshu CE; Rohrmann S; McGlynn KA; Nyante SJ; Bradwin G; Dobs AS; Kanarek N; Nelson WG; Platz EA
    Prostate; 2015 Aug; 75(11):1167-76. PubMed ID: 25919471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25-84 Years from the Busselton Health Study.
    Chan YX; Knuiman MW; Divitini ML; Handelsman DJ; Beilby JP; Yeap BB
    Horm Cancer; 2018 Dec; 9(6):391-398. PubMed ID: 30097782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.